MCL1 and breast cancer: Pre-treatment with the inhibitor MG132 followed by CHX exposure resulted in no significant change in the Mcl-1 or Bcl-2 levels in the breast cancer cell lines MDA-MB-231 (Figure 3A), MDA-MB-468 and MCF-7 (data not shown).